FDA Issues Warning to Novo Nordisk Over Delayed Adverse Event Reporting

The United States Food and Drug Administration (FDA) has formally reprimanded the Danish pharmaceutical company Novo Nordisk for failing to report suspected adverse reactions to medications within the required timeframe. This action followed an inspection in early 2025, which identified significant lapses in the company's post-marketing surveillance obligations.

The investigation highlighted that Novo Nordisk did not promptly notify authorities about several serious incidents related to the use of semaglutide, a medication marketed under brand names such as Ozempic and Wegovy. Among the incidents cited were three deaths, including one attributed to suicide. The FDA noted that not only were these cases reported late, but the suicide incident was also insufficiently investigated by the company, falling short of regulatory requirements.

Pharmaceutical companies are mandated to forward any reports of possible adverse drug reactions to regulatory bodies within specified periods, particularly when serious outcomes such as death are involved. The agency's warning letter described Novo Nordisk's non-compliance as a serious violation of these safety protocols. In response, Novo Nordisk stated its commitment to addressing the deficiencies and to fulfilling the regulatory demands outlined by the FDA.

Semaglutide, classified as a GLP-1 receptor agonist, has previously been scrutinized for its potential association with increased risk of suicidal thoughts or behavior. However, a comprehensive risk assessment conducted by the European Medicines Agency (EMA) in April 2024 found no evidence supporting a causal link between semaglutide and suicidal tendencies or actions. Despite this finding, regulatory expectations remain high regarding the timely and thorough reporting of all suspected adverse events.

In a separate matter, Novo Nordisk had recently been the subject of another warning from the FDA, this time regarding marketing practices related to its semaglutide-based products in the United States. The agency expressed concerns about the accuracy and appropriateness of promotional materials disseminated by the company.

The FDA, aiming to increase transparency and efficiency in monitoring drug safety, has introduced a new Adverse Event Monitoring System (AEMS). Launched on March 11, this public portal integrates data from seven different reporting databases, encompassing medications, vaccines, cosmetics, and food products for humans and animals. The system is designed to provide real-time access to adverse event data, thereby replacing the previous system of quarterly reports. This advancement is expected to streamline regulatory oversight, improve data accessibility, and reduce operational costs by approximately $120 million over the next five years.

Each year, the FDA receives around six million reports of adverse events across its various platforms. The agency's latest digital initiative is part of a broader effort to enhance pharmacovigilance and ensure public safety by facilitating easier and faster access to critical information on product-related risks.

The developments underscore the importance for pharmaceutical companies to maintain strict adherence to regulatory standards for adverse event reporting, as well as the ongoing commitment of health authorities to protect patient safety through robust surveillance and transparent communication.